Actively Recruiting
SGLT2i in Kidney Stones
Led by University of Chicago · Updated on 2026-01-12
32
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
Sponsors
U
University of Chicago
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones. Previous studies in those without kidney stones found that empagliflozin increased urinary citrate levels without raising urine pH. The investigators are testing whether similar effects occur in people with a history of kidney stones. Participants will take empagliflozin daily for 4 weeks. The investigators will collect 24-hour urine samples before and after treatment to measure various factors that influence stone formation, including citrate levels, pH, and calculated stone formation risk. The investigators will enroll 32 participants: 16 with a history of calcium oxalate stones and 16 with calcium phosphate stones. Results from this study may inform future larger clinical trials investigating empagliflozin as a kidney stone prevention strategy.
CONDITIONS
Official Title
SGLT2i in Kidney Stones
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- History of at least one calcium phosphate stone with at least 50% of stone material on recent analysis, or
- History of at least one calcium oxalate stone with at least 50% of stone material on recent analysis
- Balanced numbers of male and female participants
You will not qualify if you...
- History of mainly brushite, uric acid, cysteine, or struvite stones
- History of severe acid-base abnormalities or urine citrate less than 100 mg/day or greater than 1500 mg/day
- Inability to stop diuretics or alkali supplements during the study period
- Use of drugs affecting proximal tubule function (e.g., topiramate)
- Diagnosis of complete distal renal tubular acidosis
- Diagnosis of chronic kidney disease with eGFR less than 60 mL/min/1.73m2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here